Safety and Tolerability of Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% (HP/TAZ) Lotion in Patients With Moderate-to-Severe Plaque Psoriasis: Results From a 1-Year, Open-Label Study

Abstract not available.

Long‐term safety and efficacy of a fixed‐combination halobetasol propionate 0.01%/tazarotene 0.045% lotion in moderate‐to‐severe plaque psoriasis: phase 3 open‐label study

Journal of the European Academy of Dermatology and Venereology ◽

10.1111/jdv.17113 ◽

2021 ◽

Author(s):

M.G. Lebwohl ◽

L. Stein Gold ◽

K. Papp ◽

G. Han ◽

D.M. Pariser ◽

...

Keyword(s):

Plaque Psoriasis ◽

Fixed Combination ◽

Open Label ◽

Phase 3 ◽

Open Label Study ◽

Label Study ◽

Safety And Efficacy ◽

Long-term safety results from a phase 3 open-label study of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis

10.1016/j.jaad.2018.09.002 ◽

2019 ◽

Vol 80 (1) ◽

pp. 282-285 ◽

Cited By ~ 8

Author(s):

Mark G. Lebwohl ◽

Jeffrey L. Sugarman ◽

Linda Stein Gold ◽

David M. Pariser ◽

Tina Lin ◽

...

Keyword(s):

Plaque Psoriasis ◽

Fixed Combination ◽

Open Label ◽

Phase 3 ◽

Open Label Study ◽

Label Study ◽

A long-term, open-label study of the safety and efficacy of oral tazarotene in moderate to very severe plaque psoriasis

10.1016/j.jaad.2003.10.012 ◽

2004 ◽

Vol 50 (3) ◽

pp. P2 ◽

Cited By ~ 1

Author(s):

Alan Menter ◽

Deborah Lew-Kaya ◽

Frederick Beddingfield ◽

Patricia S. Walker

Keyword(s):

Plaque Psoriasis ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Safety And Efficacy ◽

Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: Results from a phase 2 open-label study

10.1016/j.jaad.2019.08.019 ◽

2020 ◽

Vol 82 (2) ◽

pp. 389-397 ◽

Cited By ~ 7

Author(s):

Amy S. Paller ◽

Ying Hong ◽

Emily M. Becker ◽

Raul de Lucas ◽

Maria Paris ◽

...

Keyword(s):

Plaque Psoriasis ◽

Pediatric Patients ◽

Phase 2 ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Combined treatment with low-dose cyclosporine and calcipotriol/betamethasone dipropionate ointment for moderate-to-severe plaque psoriasis: a randomized controlled open-label study

Journal of Dermatological Treatment ◽

10.3109/09546634.2011.565017 ◽

2011 ◽

Vol 23 (4) ◽

pp. 255-260 ◽

Cited By ~ 12

Author(s):

Gino A. Vena ◽

Antonia Galluccio ◽

Michele Pezza ◽

Michelangelo Vestita ◽

Nicoletta Cassano

Keyword(s):

Plaque Psoriasis ◽

Low Dose ◽

Combined Treatment ◽

Betamethasone Dipropionate ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Severe Plaque Psoriasis ◽

Randomized Controlled ◽

Calcipotriol Betamethasone

Open-label study of etanercept treatment in patients with moderate-to-severe plaque psoriasis who lost a satisfactory response to adalimumab

British Journal of Dermatology ◽

10.1111/bjd.15381 ◽

2017 ◽

Vol 177 (2) ◽

pp. 411-418 ◽

Cited By ~ 4

Author(s):

J. Bagel ◽

S. Tyring ◽

K.C. Rice ◽

D.H. Collier ◽

G. Kricorian ◽

...

Keyword(s):

Plaque Psoriasis ◽

Open Label ◽

Etanercept Treatment ◽

Open Label Study ◽

Label Study ◽

Severe Plaque Psoriasis ◽

Satisfactory Response

Safety and efficacy of apremilast in pediatric patients with moderate to severe plaque psoriasis: Results from a phase 2 open-label study

10.1016/j.jaad.2019.06.455 ◽

2019 ◽

Vol 81 (4) ◽

pp. AB120

Keyword(s):

Plaque Psoriasis ◽

Pediatric Patients ◽

Phase 2 ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Safety And Efficacy ◽

25709 Halobetasol propionate lotion 0.05% in patients 12 to 16 years 11 months of age with plaque psoriasis: Results from an open label study evaluating adrenal suppression potential

10.1016/j.jaad.2021.06.291 ◽

2021 ◽

Vol 85 (3) ◽

pp. AB66

Author(s):

Vivian Laquer ◽

David Davidson ◽

Andrea Nguyen ◽

Tien Nguyen

Keyword(s):

Plaque Psoriasis ◽

Adrenal Suppression ◽

Open Label ◽

Open Label Study ◽

Label Study

Effectiveness of weekly azathioprine pulse in the treatment of chronic plaque psoriasis: an open-label study

Clinical and Experimental Dermatology ◽

10.1111/ced.12887 ◽

2016 ◽

Vol 41 (7) ◽

pp. 717-722 ◽

Cited By ~ 2

Author(s):

P. Verma ◽

K. K. Verma ◽

N. Khanna ◽

S. Gupta ◽

N. Bhari

Keyword(s):

Plaque Psoriasis ◽

Chronic Plaque Psoriasis ◽

Open Label ◽

Open Label Study ◽

Label Study

A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis

10.1016/j.jaad.2014.07.048 ◽

2014 ◽

Vol 71 (6) ◽

pp. 1176-1182 ◽

Cited By ~ 69

Author(s):

Kenneth B. Gordon ◽

Craig L. Leonardi ◽

Mark Lebwohl ◽

Andrew Blauvelt ◽

Gregory S. Cameron ◽

...

Keyword(s):

Monoclonal Antibody ◽

Plaque Psoriasis ◽

Efficacy And Safety ◽

Chronic Plaque Psoriasis ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Interleukin 17A